Results 11 to 20 of about 98,145 (299)

Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison

BMJ Open, 2023
Objectives Pakistan has a hepatitis C virus (HCV) infection prevalence of 6%–9% and aims to achieve World Health Organisation (WHO) targets for elimination of HCV by the year 2030.
Louis P Garrison, Joseph B Babigumira, Samantha Clark, Saeed S Hamid, James K Karichu, Mindy M Cheng, Maciej B Maniecki   +6 more
doaj   +1 more source

Structure-activity relationships of fluorene compounds inhibiting HCV variants [PDF]

, 2020
Approximately 71 million people suffer from hepatitis C virus (HCV) infection worldwide. Persistent HCV infection causes liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, resulting in approximately 400,000 deaths ...
Gadhe, Changdev G., JANG, SUNG KEY, Keum, Gyochang, Kim, Byeong Moon, Kim, Hee Sun, Kohara, Michinori, Lee, Jae Seung, Moon, Heejo, Mun, Jaegon, Pae, Ae Nim, You, Youngsu   +10 more
core   +1 more source

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source

ANTI - HCV : DIAGNOSI DI LABORATORIO

Microbiologia Medica, 2005
-
A. Migliozzi, M.P. Cocco
doaj   +1 more source

Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. [PDF]

PLoS ONE, 2014
The aim of this study is to explore the prevalence of hepatitis C virus (HCV) infection among injection drug users (IDUs) with and without human immunodeficiency virus (HIV) infection in southern Taiwan.
Meng-Hsuan Hsieh, Jih-Jin Tsai, Ming-Yen Hsieh, Chung-Feng Huang, Ming-Lun Yeh, Jeng-Fu Yang, Ko Chang, Wei-Ru Lin, Chun-Yu Lin, Tun-Chieh Chen, Jee-Fu Huang, Chia-Yen Dai, Ming-Lung Yu, Wan-Long Chuang   +13 more
doaj   +1 more source

Incidence, prevalence, and clinical course of hepatitis C following liver transplantation [PDF]

, 1992
Hepatitis C virus (HCV) is the agent responsible for posttransfusion hepatitis. The incidence, timing, and clinical course of HCV positive hepatitis in liver transplant recipients are unknown.
A.Jake Demetris, Aach, Alter, Barcena, Barrera, Brillanti, Choo, Colombo, David H. Van Thiel, Esteban, Esteban, Feinman, Grandele, Gray, Gunjan Shah, Hernandez, Jessica H. Lewis, Judith S. Gavaler, Kaplan, Knodell, Kuo, Kühnl, Mattsson, McFarlane, McHutchison, Noel, Poel, Read, Read, Rumi, Saturo Todo, Simonetti, Stevens, Thomas E. Starzl, Trainer, Weiner   +35 more
core   +1 more source

Anti HCV seropozitif kişilerde moleküler HCV RNA test sonuçlarının değerlendirilmesi

Turkish Journal of Family Practice, 2013
Amaç: Bu araştırmada, Anti HCV pozitif kişilerin HCV RNA viral yük miktarları incelenerek, akut enfeksiyon sonrası iyileşme, kronikleşme, hastaların tedavi yanıtları ve bunların cinsiyet ile iliflkisinin değerlendirilmesi amaçlanmıştır.
Cem Çelik, Mustafa Gökhan Gözel, Fatma Dayı, Rakibe Kaygusuz, Mustafa Zahir Bakıcı   +4 more
doaj   +1 more source

A single site study to investigate the current prevalence of anti‐hepatitis C virus antibody among substance use disorder patients in Hiroshima—Insufficient testing and diagnosis

Neuropsychopharmacology Reports, 2023
Aims Hepatitis C virus (HCV) infection among drug users presents an important public health problem; however, little recognition and few approaches to address this issue in Japan.
Ariyuki Kagaya, Yuko Nagaoki, Satomi Shimura, Katsuyoshi Kawana, Kazuaki Chayama   +4 more
doaj   +1 more source

Identification of novel neutralizing determinants for protection against HCV

Hepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua, Anne F. Pihl, Anna Offersgaard, Rodrigo Velázquez‐Moctezuma, Carlos R. Duarte Hernandez, Elias H. Augestad, Ulrik Fahnøe, Christian K. Mathiesen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jens Bukh, Judith M. Gottwein   +12 more
wiley   +1 more source

Multicenter evaluation of the new Alinity s anti-HCV II assay for routine hepatitis C virus blood screening

Journal of Clinical Virology Plus, 2023
Background: Anti-HCV immunoassays remain the primary serologic test for HCV screening among blood donors. Since 1990s, Anti-HCV assays have evolved and those currently available detect infection earlier and have improved sensitivity and specificity ...
Wai-Chiu Tsoi, Catriona Simpson, Lisa Jarvis, Alan Smith, Ninette Robbins, Ramune Sepetiene, Sonu Bhatnagar   +6 more
doaj   +1 more source